Full-Time

State Access Manager

Confirmed live in the last 24 hours

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior, Expert

Bhubaneswar, Odisha, India

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor's degree in Bioscience, Public Health, or related field.
  • Minimum 8 years of overall experience.
  • Minimum 1 year of relevant experience in market access, public health, or related field.
Responsibilities
  • Map and engage state stakeholders to create consensus for strategic therapy areas of AstraZeneca India.
  • Collaborate with Medical, Commercial, Corporate Affairs, Legal, and Compliance teams to identify, ideate, and strategize state access solutions.
  • Implement access solutions in partnership with state governments to enhance patient outcomes.
  • Create proposals for state governments in collaboration with cross-functional teams.
  • Provide strong evidence and health economics outcomes to shape health policies and mobilize funds for enabling access to eligible patients.
  • Partner with states to improve awareness, diagnosis, and treatment to close the care gap in the state.
Desired Qualifications
  • Doctorate or medical professional background preferred.
  • MBA would be an advantage.

AstraZeneca focuses on discovering, developing, and selling prescription medicines, primarily in three areas: Oncology (cancer), Cardiovascular, Renal & Metabolism (heart and kidney diseases), and Respiratory & Immunology (lung and immune system diseases). Their products are developed through extensive research and development, which includes rigorous clinical trials and regulatory approvals before reaching the market. What sets AstraZeneca apart from competitors is their commitment to collaboration, exemplified by their Open Innovation program that shares resources with the scientific community, and their A.Catalyst Network, which connects health innovation hubs globally to enhance drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and improving patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery enhances AstraZeneca's R&D efficiency.
  • Real-world evidence streamlines AstraZeneca's drug approval processes.
  • Personalized medicine aligns with AstraZeneca's focus on precision medicine.

What critics are saying

  • AI tool for breast cancer may face challenges due to minority underrepresentation.
  • Investment in Dunkirk may be at risk from changing French regulations.
  • Imfinzi faces competitive pressures from similar immunotherapies affecting market share.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapy areas.
  • The A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • Open Innovation program accelerates drug discovery by sharing compounds and technologies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

Europawire
Apr 8th, 2025
AstraZeneca Unveils Breakthrough Data on Vaccines and Antibody Therapies for Infections

AstraZeneca unveils breakthrough data on vaccines and antibody therapies for infections.

Delcade
Apr 4th, 2025
Foreign investment in France: Key trends, legal considerations (2024)

AstraZeneca invested €365 million in expanding its production lines in Dunkirk.